Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study
1 other identifier
observational
83
1 country
1
Brief Summary
In this province, optometrists are often responsible for contacting the retinal specialists' office to arrange patients to be examined for suspected emergencies or more routine referrals related to the eye. This is often done by faxing a referral form to the specialists' office, where the retinal specialist will examine the information presented in the referral form and make a decision on when the patient should be seen. This current method has some important considerations, such as the difficulty of transmitting clear images of the back of the eye over fax. Having this information could help the retinal specialist in determining when the patient should be seen, especially in terms of booking additional tests or when treatment should be given. Teleophthalmology is a branch of telemedicine that delivers eye care through digital equipment and telecommunications technology. It offers some unique advantages, such as the ability to be integrated with electronic health records, the ability to be viewed by multiple members of the health care team, and potentially reduce wait times and travel times to the ophthalmologist. However, there is no comparison known to the study team between whether patients being referred from optometrists to retina specialists through a teleophthalmology system will be treated earlier than patients through a conventional fax system. This study aims to examine and provide more information on this topic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 9, 2013
CompletedFirst Posted
Study publicly available on registry
July 16, 2013
CompletedStudy Start
First participant enrolled
November 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2022
CompletedMay 22, 2023
May 1, 2023
8.2 years
July 9, 2013
May 19, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time to Treatment
Defined as defined as the time between when the retina specialist reviews the information collected by either system to when the patient receives treatment by the specialist in the clinic.
Average 5-6 Weeks.
Secondary Outcomes (5)
Maximum wait time
Can range from 2-6 weeks.
Minimum Wait Time
Can range from 2-6 weeks.
Mean wait time
Can range from 2-6 weeks.
Travel time
Can range from 30 minutes or greater.
Travel Distance
Can range from 1 kilometer or greater.
Study Arms (2)
Tele-ophthalmology Referral Group
This group includes patients referred to a retinal specialist via a teleophthalmology referral system.
Conventional Referral Group
This group includes patients referred to a retinal specialist via a conventional fax system.
Eligibility Criteria
The study population includes patients who are referred from an optometrist either participating in the teleophthalmology referral system or via conventional fax referrals with a provisional diagnosis of possible wet AMD or DME to any of the physician investigators.
You may qualify if:
- Aged greater than 18 years,
- Able to provide informed consent,
- Referred from an optometrist either participating in the teleophthalmology referral system or via conventional fax referrals with a provisional diagnosis of possible wet AMD or DME to any of the physician investigators.
You may not qualify if:
- Patients with a presumed diagnosis of wet AMD and/or DME at the time of referral who previously had diagnostic imaging (ex. fundus images, OCT images) performed as part of the referral will be excluded;
- Patients unable to tolerate fluorescein angiography (FA);
- Patients unable to travel to the retina practice for treatment or further testing,
- Patients unable to fully understand the study requirements and provide informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
St. Joseph's Healthcare Hamilton King Campus
Hamilton, Ontario, L8G5E4, Canada
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 9, 2013
First Posted
July 16, 2013
Study Start
November 1, 2013
Primary Completion
January 1, 2022
Study Completion
February 1, 2022
Last Updated
May 22, 2023
Record last verified: 2023-05